Plasma Nesfatin-1 Research Articles

Investigation of the Relationship between Plasma Nesfatin-1 Levels and Neutering in Dogs.

Neutering of dogs, whether male or female, provides various benefits such as contraception, population control, and the prevention of reproductive disorders and undesirable sexual behaviors. However, it is also associated with an increased risk of obesity, which may be directly linked to post-neutering hormonal changes. Our study aims to determine the effects of neutering on plasma levels of nesfatin-1, serotonin, dopamine, TSH, and T4-hormones implicated in obesity and metabolic regulation. Fourteen dogs (seven males and seven females), aged between 1 and 3 years, were included in this study. Male dogs underwent orchiectomy and females underwent ovariohysterectomy. Blood samples were collected before surgery and on days 7 and 14 post-operatively to measure the plasma levels of these hormones using ELISA. The results showed a significant decrease in nesfatin-1, serotonin, and T4 levels, along with a significant increase in TSH levels in both male and female dogs post-neutering. While these hormonal changes are likely part of the body's adaptive response to neutering, they may represent a potential mechanism that contributes to the long-term tendency toward obesity in neutered dogs.

The Relation between Plasma Nesfatin-1 Levels and Aggressive Behavior in Pit Bull Dogs.

Aggression is a prevalent and concerning behavioral issue in dogs. Pit Bull dogs, known for their high levels of aggression, are recognized as a focus of concern in society. In our study, we aimed to investigate the behavioral characteristics of Pit Bull dogs and explore the potential roles of peptides involved in the neurobiology of aggression. Initially, female, and male dogs underwent aggression tests, and their aggression levels were categorized. Plasma nesfatin-1, serotonin, oxytocin, and dopamine levels were quantified using ELISA, with blood samples collected after a 24 h fasting period and 2 h post-refeeding. Our findings indicate that aggression in Pit Bull dogs correlates with decreased plasma nesfatin-1, serotonin, and oxytocin levels, while dopamine levels increase. The study's findings indicate that fasted dogs exhibited lower plasma levels of nesfatin-1, serotonin, and dopamine, while plasma oxytocin levels were higher. Furthermore, while the research findings do not suggest a significant relationship between the severity of aggression and the gender of the dog, male Pit Bull breeds appear to have higher plasma nesfatin-1 and serotonin levels compared to their female counterparts. The study's findings demonstrate that nesfatin-1, serotonin, oxytocin, and dopamine play pivotal roles in Pit Bull dogs' aggression, indicating potential interactions among these neuropeptides at the central nervous system level.

High plasma nesfatin-1 level in Chinese adolescents with depression

Depression is a common psychiatric disorder with high prevalence and mortality rates as well as high risk of serious harm in adolescents that have significant negative impact on families and society. The feeding inhibitor Nesfatin-1 contributes to the regulation of stress and emotion. The purpose of this project was to compare the differences in the levels of Nesfatin-1 between adolescents with depression and healthy adolescents, and verify the association between the levels of Nesfatin-1 and severity of depression in adolescents. Adolescents with depression (n = 61) and healthy adolescents (n = 30) were evaluated. The Hamilton Depression Rating Scale (HAMD-17) was used to classify the adolescents with depression. Thirty-one and thirty-two was assigned to the mild-to-moderate (HAMD-17 ≤ 24) depression group and severe group (HAMD-17 > 24). Plasma Levels of Nesfatin-1 were measured by human ELISA Kit and differences among groups evaluated. Data were analyzed using the statistical software SPSS 23. HAMD-17 score was significantly higher in adolescents with depression than that in the healthy adolescents (P < 0.001). Median plasma Nesfatin-1 levels in adolescents with depression and healthy adolescents differed significantly at 37.3 pg/ml (22.1 pg/ml, 63.6 pg/ml) and 18.1 pg/ml (10.0 pg/ml, 25.7 pg/ml) (p < 0.001). A multivariate logistic regression analysis showed high plasma Nesfatin-1 concentrations were associated with increased risk of depression (OR = 0.914, 95% CI 0.87–0.96, P < 0.001). The receiver operating characteristic curve showed that the area under curve were 0.808 (95% CI 0.722–0.894, P < 0.001). Plasma Nesfatin-1 cut-off point of 32.45 pg/mL showed 59% sensitivity and 100% specificity. Median plasma Nesfatin-1 levels in the severe depression group (n = 30), mild-to-moderate depression group (n = 31), and control group (n = 30) were 53.4 pg/ml (28.2 pg/ml, 149.1 pg/ml), 29.9 pg/ml (14.5 pg/ml, 48.5 pg/ml) and 18.1 pg/ml (10.0 pg/ml, 25.7 pg/ml), and differed significantly among the three groups (P < 0.001). Median plasma level of Nesfatin-1 in males (n = 20) was 38.6 pg/ml (23.5 pg/ml, 70.1 pg/ml), while that in females (n = 41) was 37.3 pg/ml (22.0 pg/ml, 63.6 pg/ml), which was not a significant difference (P > 0.05). Plasma levels of Nesfatin-1 increased with severity of depression in adolescents and may be useful as a biomarker of depression severity. Further studies are needed in future projects.

Plasma Leptin, Nesfatin 1, NPY, and Zinc Levels in Obese and Metabolic Syndrome Children

Objective: The aim of this study is to investigate the relationship between leptin, nesfatin 1 and NPY hormones and zinc in boys and girls diagnosed with metabolic syndrome and obesity. Materials and Methods: This study included a total of 6 groups. Group 1 Boy Control, Group 2 Girl Control, Group 3 Obese Boys, Group 4 Obese Girls, Group 5 Boys with Metabolic Syndrome, Group 2 with Girls with Metabolic Syndrome. Plasma leptin, nesfatin-1, NPY (by ELISA method) and serum zinc (by AA method) levels were determined in blood samples obtained from the subjects. Results: Leptin and zinc levels were significantly higher both in boy and girl patients with metabolic syndrome than in obese and control children. Nesfatin-1 and NPY levels were significantly lower both in girl and boy obese and metabolic syndrome children compared to their control groups. Conclusion: In the current study a significant increase in plasma leptin and serum zinc levels and a significant decrease of plasma nesfatin-1 and NPY levels were observed in boys and girls with metabolic syndrome. The findings of our study show that leptin, nesfatin-1 and NPY levels may be important biomarkers in the assessment of metabolic syndrome risk in both girls and boys.

A new obesity treatment method that does not require restriction in food intake and organ resection

Background/Aim: There are numerous treatment methods available for obesity, with bariatric surgery being the most effective. However, these techniques come with the risk of serious complications. This study presents a novel obesity treatment device that can shorten the length of the small intestine without the need for surgical intervention. Methods: Our new device comprises three main components: a 25 cm long rope, with one end attached to a 1 cm diameter plastic ring and the other end attached to a 2 mm diameter, 5 g sphere. Twenty-one male Wistar albino rats (6 months old, mean weight 400 g, outbred) were divided into three equal groups. Laparotomy and gastrotomy were performed on the subjects in Group 1, and all three parts of the device were placed into the gastrointestinal tract. In Group 2, only the plastic ring was placed in the stomach, and in Group 3, only a gastrotomy was performed. All subjects were followed for 3 months, during which their body weight, serum ghrelin, leptin, and nesfatin-1 levels were recorded, and the amount of food they consumed was measured. After sacrificing the animals, the stomach, proximal, and distal intestines were resected for histopathological evaluation. Results: The subjects in Group 1 experienced weight loss, whereas those in Groups 2 and 3 showed statistically significant weight gain (P&lt;0.001 and P=0.022, respectively). Serum ghrelin levels were significantly increased in Groups 1 and 3 (P=0.015 and 0.031, respectively), while serum leptin levels were significantly decreased in Group 1 (P=0.015). Plasma nesfatin-1 levels were significantly higher in Group 1 compared to the other groups (P=0.014). There was no statistically significant difference in feed consumption between the groups. Histopathological examination revealed significantly higher fibrosis and inflammation scores in the proximal small intestine of Group 1 compared to the other groups (P=0.008 and P=0.005, respectively). Conclusions: This new device facilitates rapid and effective weight loss without the need for restricting oral food intake or organ resection. Changes in serum ghrelin, leptin, and nesfatin-1 levels did not affect these results. We hypothesize that the effective weight loss is linked to the shortening of the small intestine length. Our future plans involve modifying the device for endoscopic application in humans.

Hypothalamic Nesfatin-1 Resistance May Underlie the Development of Type 2 Diabetes Mellitus in Maternally Undernourished Non-obese Rats.

Intrauterine growth retardation (IUGR) poses a high risk for developing late-onset, non-obese type 2 diabetes (T2DM). The exact mechanism underlying this phenomenon is unknown, although the contribution of the central nervous system is recognized. The main hypothalamic nuclei involved in the homeostatic regulation express nesfatin-1, an anorexigenic neuropeptide and identified regulator of blood glucose level. Using intrauterine protein restricted rat model (PR) of IUGR, we investigated, whether IUGR alters the function of nesfatin-1. We show that PR rats develop fat preference and impaired glucose homeostasis by adulthood, while the body composition and caloric intake of normal nourished (NN) and PR rats are similar. Plasma nesfatin-1 levels are unaffected by IUGR in both neonates and adults, but pro-nesfatin-1 mRNA expression is upregulated in the hypothalamus of adult PR animals. We find that centrally injected nesfatin-1 inhibits the fasting induced neuronal activation in the hypothalamic arcuate nucleus in adult NN rats. This effect of nesfatin-1 is not seen in PR rats. The anorexigenic effect of centrally injected nesfatin-1 is also reduced in adult PR rats. Moreover, chronic central nesfatin-1 administration improves the glucose tolerance and insulin sensitivity in NN rats but not in PR animals. Birth dating of nesfatin-1 cells by bromodeoxyuridine (BrDU) reveals that formation of nesfatin-1 cells in the hypothalamus of PR rats is disturbed. Our results suggest that adult PR rats acquire hypothalamic nesfatin-1-resistance, probably due to the altered development of the hypothalamic nesfatin-1 cells. Hypothalamic nesfatin-1-resistance, in turn, may contribute to the development of non-obese type T2DM.

Effects of different feeding methods on neuropeptide nesfatin-1 and irisin in turkeys

In this study, the effects of different methods of feeding turkeys on the neuropeptide nesfatin-1 and the hormone irisin were evaluated. A total of 90 turkeys were distributed to three treatment groups, namely T1: conventional system, T2: 50% feed and pasture, and T3: pasture. There were 30 birds in each group with three random replications. The birds were fed for 18 weeks. At the end of the study, blood was collected from 10 birds of each group. Plasma nesfatin-1 and irisin levels were measured with an enzyme-linked immunoassay. The nesfatin-1 levels of male turkeys in T1, T2, and T3 were 0.76 ± 0.1 ng/m, 0.41 ± 0.1 ng/ml, and 1.24 ± 0.2 ng/ml, respectively. Nesfatin-1 levels in the female turkeys in T1, T2 and T3 were 0.53 ± 0.07 ng/ml, 1.18 ± 0.3 ng/ml, 1.32 ± 0.1 ng/ml, respectively. The irisin levels in the male turkeys in T1, T2, and T3 were 575.93 ± 42.5 pg/ml, 188.39 ± 1.8 pg/ml, and 607.54 ± 24.1 pg/ml, respectively. Irisin levels of the female turkeys in T1, T2 and T3 were 603.20 ± 42.2 pg/ml, 241.42 ± 18.4 pg/ml, and 399.29 ± 21.5 pg/ml, respectively. Because nesfatin-1 is involved in regulating food intake, food intake by turkeys might differ, depending on the management system. Different management systems might also alter irisin secreation because it can be induced by exercise.

Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study

BackgroundNesfatin-1, a novel adipokine and dipeptidyl peptidase-4 (DPP4), a mam malian serine protease, are potent factors of atherosclerosis. In the present cross-sectional study, we investigated whether the plasma nesfatin-1 and DPP4 is associated with the prevalence and severity of coronary artery disease (CAD) with and without diabetes mellitus (DM).MethodsWe consecutively enrolled a total of 240 patients with significant CAD (previous revascularization or angiographically-proven coronary artery stenosis > 50%) presented with either unstable angina (UA, N = 76) or stable chronic CAD (SCAD, N = 165). 85 patients with at least 2 classical cardiovascular risk factors but without significant CAD served as controls. The severity of CAD was assessed using coronary angiography by the Gensini score. Clinical parameters, glycemic and lipid profile, high-sensitivity CRP (hsCRP), nesfatin-1 and DPP4 levels were assayed.ResultsNo differences were found for age, sex, hypertension and diabetes distribution between groups. Low nesfatin-1 levels were found in both CAD groups (UA & SCAD) with respect to controls. The difference between UA and SCAD groups was marginally non-significant. There was a significant increase of DPP4 along UA to SCAD and control groups. Differences between groups remained unchanged in non-diabetic participants. Nesfatin-1 significantly correlated to hsCRP (r = − 0.287, p = 0.036), HOMA-IR (r = − 0.587, p = 0.007) and hyperlipidemia (r = − 0.331, p = 0.034). DPP4 was significantly associated with hs-CRP (r = 0.353 p < 0.001) and FPG (r = 0.202, p = 0.020) in univariate analysis, but those correlations were lost in multiple regression analysis. There was a negative correlation between nesfatin-1 and the severity of CAD, quantified by the Gensini score (r = − 0.511, p < 0.001), but no association was found for DPP4.ConclusionsSerum DPP4 levels are increased in patients with CAD, while serum nesfatin-1 levels have a negative association with both the incidence and the severity of CAD. These results are independent of the presence of diabetes mellitus. In addition, both peptides have a strong association with hsCRP.Trial registration ClinicalTrials.gov Identifier: NCT00306176

Plasma Nesfatin-1: Potential Predictor and Diagnostic Biomarker for Cognitive Dysfunction in T2DM Patient.

PurposeNesfatin-1 plays a crucial role in glucose metabolism and cognitive function. This study aimed to investigate the correlation between plasma nesfatin-1 levels and clinical indicators and cognitive function in patients with type 2 diabetes mellitus (T2DM).MethodsDemographic and medical history data, physical examination, and biochemical test results of 132 T2DM patients were collected. The plasma concentrations of nesfatin-1, C-reactive protein (CRP), interleukin-6 (IL-6), soluble triggering receptors expressed on myeloid cells 1 (sTREM1), and sTREM2 in T2DM patients were measured. Cognitive function was evaluated using the Behavior Rating Inventory of Executive Function-Adult (BRIEF-A). The patients were divided into two groups: a low-nesfatin-1 group (n = 75) and a high-nesfatin-1 group (n = 57) based on a plasma nesfatin-1 concentration less than or above the 50th percentile value of all the samples.ResultsThe results showed that plasma HbA1c levels were positively correlated with CRP, IL-6, sTREM1, and sTREM2 levels in patients with T2DM (P < 0.05). Plasma nesfatin-1 concentrations were positively associated with diabetes-related biochemical indicators including glycated haemoglobin (HbA1c), insulin, and homeostatic model assessment of insulin resistance (HOMA-IR), and inflammation-related indicators including CRP, IL-6, sTREM1, and sTREM2 among patients with T2DM (P < 0.05). Moreover, T2DM patients with high nesfatin-1 levels showed higher HbA1c and fasting plasma glucose (FPG) levels (P < 0.05). Furthermore, T2DM patients with high nesfatin-1 levels also showed higher BRIEF-A scores (P = 0.01). Additionally, T2DM patients with high total scores of BRIEF-A (scores > 50th percentile) could be identified with a sensitivity of 59.1% and a specificity of 72.7% by nesfatin-1.ConclusionThese findings indicate that plasma nesfatin-1 might be involved in the T2DM-associated comorbidities and the development of cognitive dysfunction, and the mechanism underlying this involvement is related to the imbalance in the expression of CRP, IL-6, sTREM1, and sTREM2 levels.

Investigation of Ram Sperm Acrosome Integrity in relation with Seminal Plasma Homocysteine and Nesfatin-1 Levels

Bu calismada homosistein, nesfatin-1 duzeyleri ile akrozom butunlugu arasindaki iliskinin arastirilmasi amaclanmistir. Ejakulatlar, suni vajen yontemiyle alti yetiskin koctan alindi ve toplanan ejakulatlar bes gruba bolunerek 37 °C'de sulandirildi. Sperma sulandirilmasinda kolesterol yuklu siklodekstrin (CLC) 1.5 ve 2.5 mg, kolesterol yuklu 7-dehidrokolesterol (7-DCLC) 1.5 ve 2.5 mg iceren veya katki maddesi icermeyen (kontrol) sulandiricilar kullanildi. Tum gruplardaki sperma ornekleri 5 °C' de sogutulduktan sonra sivi nitrojen buharinda (-110~-120° C) donduruldu. Sivi nitrojen icinde saklanan sperma ornekleri incelenmek icin 38 °C ve 30 saniyede cozduruldu. Akrozom butunlugu, FITC-PNA boyama ile incelendi. Homosistein (HCY) ve nesfatin-1 testleri ELISA yontemi ile yapildi. CLC 1.5 ve 2.5 mg gruplarinda homosistein seviyeleri kontrol grubuna (1.36±0.9) gore daha dusuk bulundu (0.67±0.11, 0.61±0.26) (p 0.05). 2.5 mg CLC'de akrozom butunlugu bozulmamis sperma hucrelerinin oranlari (65.88±2.84) kontrol grubuna (52.38±2.97) gore daha yuksek bulundu (p<0.05). Sperma akrozom butunlugu, cozum sonu koc spermasinda HCY seviyesi (r =-,630) ile negatif, nesfatin-1 seviyeleri (r =, 460) ile pozitif korelasyon gosterdi. Sonuc olarak, CLC'nin akrozom butunlugu uzerinde kriyoprotektif bir etki gosterdigi ve HCY seviyesi uzerinde faydali oldugu belirlenmistir.

Decreased level of plasma nesfatin-1 in rats exposed to cell phone radiation is correlated with thyroid dysfunction, oxidative stress, and apoptosis

Context: Exposure to Electomagnetic radiation fields of cell phones causes thyroid dysfunction and a previous study revealed that nesfatin-1 may affect functions of the thyroid gland.Objective: To study the role of nesfatin-1 on functions of rat’s thyroid gland exposed to EMRF.Materials and methods: Thirty adult male rats were divided equally into 3 groups as group I, group II and group III. The experiment extended for 30 days then the plasma nesfatin-1 level, thyroid functions, and thyroid tissue oxidative stress were assessed. Also; histological and immunohistochemical study studies were done to evaluate structural and apoptotic changes of the thyroid gland.Results: There was a significant decrease in plasma nesfatin-1 level and thyroid functions with an increase in oxidative stress and apoptosis. Interestingly, there was a correlation between nesfatin-1 level and markers of thyroid function, oxidative stress and apoptosis.Conclusion: Nesfatin-1 plays a role in thyroid dysfunctions of rats exposed to mobile phone radiation.

Effects of Acute and Chronic Exercises on Plasma Nesfatin-1 Levels in Young Adults

Effects of Acute and Chronic Exercises on Plasma Nesfatin-1 Levels in Young Adults

Evidence of a Relationship Between Plasma Leptin, Not Nesfatin-1, and Craving in Male Alcohol-Dependent Patients After Abstinence.

The goal of this study was to determine whether the plasma leptin, nesfatin-1, cortisol, brain-derived neurotrophic factor (BDNF), and inflammatory cytokines could be used as potential biomarkers for the degree of craving in the alcohol-dependent patients after 1 month of abstinence. A total of 83 patients with alcohol use disorder (AUD) and 61 healthy subjects were assessed. Patients with AUD were selected from Department of Material Dependence, Anhui Mental Health Center, and subjects in the control group were selected from healthy volunteers. The Alcohol Urge questionnaire Scale (AUQ) was used to evaluate the extent of craving for alcohol, and the Michigan Alcoholism Screening Test (MAST), the Fagerstrom Test for Nicotine Dependence (FTND), the Self-Rating Anxiety Scale (SAS), and the Self-Rating Depression Scale (SDS) were also assessed in patients with AUD. Enzyme-Linked Immunosorbent Assay (ELISA) was used for the measurement of plasma leptin, nesfatin-1, cortisol, BDNF, Interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-α (TNF-α) levels. Compare with healthy controls, the average leptin, leptin/BMI, IL-6, CRP, and TNF-α levels in patients with AUD were significantly increased, while the BDNF levels were significantly decreased. Moreover, the partial correlational analysis showed that the AUQ scores of the alcohol-dependent patients were positively correlated with the plasma leptin levels (r = 0.613, P < 0.001), rather than nesfatin-1 (r = 0.066, P = 0.569) after controlling for age as covariate. Furthermore, plasma nesfatin-1 levels were found to be correlated with the SDS scores (r = 0.366, P = 0.001) in the AUD group. In addition, plasma leptin levels were positively associated with the plasma IL-6 (r = 0.257, P = 0.033), CRP (r = 0.305, P = 0.011), and TNF-α (r = 0.311, P = 0.009) levels, and negatively associated with the BDNF levels (r = −0.245, P = 0.042) in patients with AUD. These results suggest that plasma leptin, but not nesfatin-1, might be a potential biomarker for the degree of craving in alcohol-dependent patients after 1 month of abstinence, the mechanism of which might be related to the dysfunction of the inflammatory cytokines and BDNF levels.

Plasma Nesfatin-1 and Insulin Resistance Changes Immediately After Circuit-Resistance Exercise and During Recovery Periods in Healthy Men

Objectives: Resistance exercise is an effective method for weight control programs, and it might be useful to understand its influence on acute body energy hemostasis changes. Therefore, the present study aimed to examine the response of nesfatin-1 and insulin resistance (IR) to acute circuit resistance exercise and their changes during recovery periods. Methods: Twelve participants (age: 22.1 ± 2.1 y, height: 176.2 ± 6.5 cm and weight: 69.0 ± 8.2 kg) attended voluntary in this research. After performing one maximal repetition (1-RM) test in a separate session for each participant, they completed circuit resistance exercise trial at 50% of 1-RM intensity. Exercise session consisted of 3 circuit of 7 exercises with 2 minutes and 30 seconds rest between circuits and exercises, respectively. All participants attended a control session with 1 week interval. After 8 - 10 hours fasting blood samples were obtained from antecubital vein before exercise, after exercise, 1-hour and 24-hour after recovery from the last exercise session, and at the same times of the rest session. Nesfatin-1, insulin and glucose were measured from plasma samples. All data series were analyzed with repeated measure ANOVA (2 × 4). Results: Data analysis revealed significant increases in nesfatin-1 and IR in response to acute circuit resistance exercise (P 0.05). Conclusions: The present study revealed that nesfatin-1 significantly increased in response to circuit resistance exercise, which suggests that plasma nesfatin-1 may have an influential role in short-term anorexia and insulin secretion immediately after exercise.

Nesfatin-1 is a potential diagnostic biomarker for gastric cancer.

The lack of reliable plasma biomarkers limits their use in the diagnosis of gastric cancer (GC). The current study aimed to determine whether plasma nesfatin-1 can be used as a novel non-invasive biomarker for the diagnosis of GC. The levels of nesfatin-1 in 40 patients with GC and 40 healthy individuals, who were selected from the Chaohu Hospital Affiliated to Anhui Medical University, were assessed. ELISA was used for the measurement of plasma nesfatin-1 levels, while immunohistochemistry was applied to determine Ki67 protein expression in GC and normal gastric tissues. The diagnostic value of plasma nesfatin-1 for GC was further assessed using receiver operating characteristic (ROC) curve analysis. The results revealed that, compared with the controls, the mean nesfatin-1 levels in patients with GC were significantly increased. Furthermore, the protein expression of Ki67 in GC tissue was significantly upregulated compared with that in normal gastric tissue. Plasma nesfatin-1 levels were also demonstrated to be correlated with Ki67 protein expression in GC tissues. Additionally, ROC curve analysis indicated the potential diagnostic value of nesfatin-1, and the area under the ROC curve (AUC) for nesfatin-1 was 0.857 (95% confidence interval, 0.769-0.946). At a threshold nesfatin-1 level of 1.075 ng/ml, the optimal sensitivity and specificity were 70.0 and 95.0%, respectively, in discriminating patients with GC from healthy controls. These results indicated that plasma nesfatin-1 may serve as a novel biomarker for the diagnosis of GC and determination of GC cell proliferation.

Sex-specific association of plasma nesfatin-1 concentrations with obesity in children.

Nesfatin-1, an anorexigenic peptide, has been associated with food intake and thermogenesis, with discordant findings in humans and scarce studies in children to date. The aim of this study was to analyze the relationship of obesity with nesfatin-1 levels in two cohorts of children. Plasma nesfatin-1 concentrations were analyzed in 6- to 9-year-olds (n=140) and 12- to 16-year-old children (n=96), including children with obesity and their sex- and age-matched normal-weight counterparts. Anthropometric measurements were assessed. Cholesterol and triglycerides were determined enzymatically, insulin concentrations were measured by radioimmunoassay using a commercial kit and nesfatin-1, leptin and hs-CRP concentrations were determined using commercial ELISA kits. Nesfatin-1 concentrations were significantly lower in younger (P=.001) and older (P=.009) girls with obesity than in their normal-weight counterparts, without showing significant differences in boys. Nesfatin-1 showed a negative significant (P<.010) correlation with weight and BMI in girls but not in boys. A significant positive correlation of nesfatin-1 levels with insulin, HOMA, and leptin levels appears in girls after adjusting by age and BMI. A significant positive correlation (P=.003) was observed between nesfatin-1 and fat mass in older children. Our study shows lower concentrations of nesfatin-1 related to obesity in girls but not in boys at two different ages. The existence of a sex-specific association between nesfatin-1 concentrations and presence of obesity highlights the need of an analysis by gender of the relationship of nesfatin-1 with obesity.

Plasma Nesfatin-1 Levels and its Relationship with Anxiety Levels in Obesity Diagnosed Population: A Controlled Study

Objective: Nesfatin-1 is a satiety neuropeptide involved in the regulation of metabolic pathways and food intake. Some studies have shown nesfatin-1 to be also associated with stress responses and stress-related behaviors. In the present study, we evaluated nesfatin-1 levels in obese individuals and investigated whether nesfatin-1 levels could be associated with anxiety levels in obese populations. Methods: Fifty-eight obese (29 anxious and 29 non-anxious) patients and 25 healthy control subjects between 18 and 65 years old were enrolled in the study. Plasma nesfatin-1 levels were measured with a commercial enzyme-linked immunosorbent assay, and anxiety levels were measured using the Hospital Anxiety and Depression Scale.Results: Plasma nesfatin-1 levels were significantly lower in both obese and anxious subjects and obese and non-anxious subjects than in the control group. No significant differences were found between the obese+anxious group and the obese+nonanxious group.Conclusion: Our results suggest that plasma nesfatin-1 levels are decreased and not associated with anxiety levels in obese populations

Plasma Nesfatin-1 Levels and its Relationship With Anxiety Levels in Obesity Diagnosed Population: A Controlled Study

Plasma Nesfatin-1 Levels and its Relationship With Anxiety Levels in Obesity Diagnosed Population: A Controlled Study

Merkezi ve periferik olarak enjekte edilen CDP-kolin’in sıçanlarda plazma nesfatin-1 seviyesi üzerine etkisi

Nesfatin-1 has a role in appetite control and energy balance. The activity of the cholinergic system also is able to affect feeding behavior. Moreover, the central cholinergic system interacts with central nesfatinergic systems. The main goal of the study was to determine the effect of intracerebroventricular (icv) and intravenous (iv) administrated CDP-choline (0.5 ve 1 μmol; icv ve 250 mg / kg; iv) on levels of plasma nesfatin-1 in the homogeneous number of male and female fasted and the satiated Wistar albino rats. The polyethylene cannula was inserted into the carotid artery and jugular vein of the rats anesthetized with sevoflurane (2–4%/100% O2) to collect blood samples and to make iv injection, respectively. For icv treatment, the lateral ventricle of rats was cannulated with guide cannula. The basal levels of plasma nesfatin-1 in the satiated rats were higher than those observed in the fasted animals. While 0.5 and 1 μmol dose of icv and/or 250 mg/kg dose of iv injected CDP-choline increased the level of plasma nesfatin-1 in the satiated rats, plasma nesfatin-1 level of the fasted animals decreased after the same dose and route of CDP-choline injection. The current findings show that CDP-choline can influence the level of plasma nesfatin-1 in the rats. The effect of the drug was different according to the food intake of the rats. These data might suggest a potential role in CDP-choline on plasma nesfatin-1 concentration.

Nesfatin-1 suppresses peripheral arterial remodeling without elevating blood pressure in mice.

Nesfatin-1 is a novel anorexic peptide hormone that also exerts cardiovascular protective effects in rodent models. However, nesfatin-1 treatment at high doses also exerts vasopressor effects, which potentially limits its therapeutic application. Here, we evaluated the vasoprotective and vasopressor effects of nesfatin-1 at different doses in mouse models. Wild-type mice and those with the transgene nucleobindin-2, a precursor of nesfatin-1, were employed. Wild-type mice were randomly assigned to treatment with vehicle or nesfatin-1 at 0.2, 2.0 or 10 μg/kg/day (Nes-0.2, Nes-2, Nes-10, respectively). Subsequently, mice underwent femoral artery wire injury to induce arterial remodeling. After 4 weeks, injured arteries were collected for morphometric analysis. Compared with vehicle, nesfatin-1 treatments at 2.0 and 10 μg/kg/day decreased body weights and elevated plasma nesfatin-1 levels with no changes in systolic blood pressure. Furthermore, these treatments reduced neointimal hyperplasia without inducing undesirable remodeling in injured arteries. However, nesfatin-1 treatment at 0.2 μg/kg/day was insufficient to elevate plasma nesfatin-1 levels and showed no vascular effects. In nucleobindin-2-transgenic mice, blood pressure was slightly higher but neointimal area was lower than those observed in littermate controls. In cultured human vascular endothelial cells, nesfatin-1 concentration-dependently increased nitric oxide production. Additionally, nesfatin-1 increased AMP-activated protein kinase phosphorylation, which was abolished by inhibiting liver kinase B1. We thus demonstrated that nesfatin-1 treatment at appropriate doses suppressed arterial remodeling without affecting blood pressure. Our findings indicate that nesfatin-1 can be a therapeutic target for improved treatment of peripheral artery disease.